- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02454634
Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)
Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)
Study Overview
Detailed Description
The patient population will be molecularly defined and include IDH1R132H mutant grade III and IV gliomas without co-deletion of 1p/19q and with loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) expression.
Within this trial, the IDH1 peptide vaccine will be administered to 39 patients.
In treatment group 1 vaccination treatment will be done alone starting 4-6 weeks post radiotherapy. In treatment groups 2 and 3 vaccination treatment will be done in parallel with temozolomide (TMZ) chemotherapy starting at day 10 of the 4th TMZ cycle (treatment group 2) or at day 10 of the 1st TMZ cycle post concomitant radiochemotherapy (treatment group 3).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Charité Berlin, Neurosurgery
-
Dresden, Germany
- University Hospital Dresden, Neurosurgery
-
Essen, Germany
- University Hospital Essen, Internal Medicine
-
Frankfurt/Main, Germany
- University Hospital Frankfurt, Neurooncology
-
Freiburg, Germany
- University Hospital Freiburg, Neurosurgery
-
Heidelberg, Germany
- University Hospital Heidelberg, Neurology Clinic
-
Munich, Germany
- LMU, University Hospital Munich
-
Tuebingen, Germany
- University Hospital Tuebingen, Neurooncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients present with histologically confirmed diagnosis of an IDH1R132H-mutated glioma (with or without measurable residual tumor after tumor resection or biopsy)
- Histology may be astrocytoma, oligodendroglioma, or oligoastrocytoma WHO grade III or IV
- Absence of chromosomal 1p/19q co-deletion in the tumor tissue
- Loss of nuclear ATRX expression in the tumor tissue (partial loss allowed)
- Availability of tumor tissue for molecular screening (FFPE bulk tissue or biopsy)
- Patients have received radiotherapy (54 - 60 Gy) alone, 3 cycles of chemotherapy with TMZ (150-200 mg/m2, 5/28 days) or standard combined radiochemotherapy with TMZ prior to enrollment.
- Patients should be immunocompetent (i.e. no concomitant treatment with dexamethasone (or equivalent), or receive stable/decreasing steroid levels not exceeding 2 mg/day dexamethasone (or equivalent) during the last 3 days prior to clinical screening; no severe lymphopenia)
- ≥18 years old, smoking or non-smoking, of any ethnic origin and gender
- Karnofsky Performance Status ≥ 70
- Ability of patient to understand character and individual consequences of the clinical trial
- Evidence of two informed consent documents personally signed and dated by the patient (or a witness in case the patient is unable to write) covering the molecular screening procedure (short IC) and the remaining trial-related procedures (extended IC) and indicating that the patient has been informed of all pertinent aspects of the study and that the patient consents to participate in the trial.
- Women of child-bearing potential (WOCBP; i.e., those who have not undergone a hysterectomy, bilateral salpingectomy and bilateral oophorectomy or who have not been post-menopausal for at least 24 consecutive months) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of the investigational medicinal product (IMP).
- WOCBP must be using an effective method of birth control to avoid pregnancy throughout the study and for 24 weeks after the last dose of the IMP. This includes two different forms of effective contraception (e.g., hormonal contraceptive and condom, IUD/IUS and condom) or sterilization, resulting in a failure rate less than 1% per year.
- Men must be willing and able to use an effective method of birth control throughout the study for up to 24 weeks after the last dose of the IMP, if their sexual partners are WOCBP (acceptable methods see above).
- Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Progressive (incl. pseudoprogression) or recurrent disease after radiation therapy, chemotherapy or radiochemotherapy based on local MRI assessment
- Previous or concurrent experimental treatment for the tumor. This includes local therapies such as interstitial radiotherapy or local chemotherapy (i.e. BCNU wafers), loco-regional hyperthermia, and antiangiogenic therapy (such as bevacizumab)
- Antitumor treatment other than standard radiotherapy and/or standard TMZ chemotherapy. Daily metronomic TMZ or intensified dosing scheduled as a substitute for maintenance TMZ cycles are not allowed. (Dose reductions of standard TMZ chemotherapy are allowed.)
Abnormal (≥ Grade 2 CTCAE v4.0) laboratory values for hematology, liver and renal function (serum creatinine). In detail the following values apply as exclusion criteria:
- Hemoglobin < 10 g/dL (6.2 mmol/L)
- White blood cell count (WBC) decrease (<3.0 x 109/L) or increase (>10.0 x 109/L)
- Absolute neutrophil count (ANC) decrease (< 1.5 x 109/L)
- Platelet count decrease (< 75 x 109/L)
- Bilirubin > 1.5 x ULN (upper limit of normal according to the performing lab's reference range)
- ALT > 3 x ULN
- AST > 3 x ULN
- GGT > 2.5 x ULN
- Serum creatinine increase (> 1.5 x ULN)
- Pregnancy and lactation
- Patients with history or presence of HIV and/or HBV/HCV
- Patients with history or known presence of tuberculosis
- Patients with severe infection(s) or signs/symptoms of infection within 2 weeks prior to the first administration of the study drug
- Patients who have received a live, attenuated vaccine within 4 weeks prior to the first administration of the study drug
- Patients with a prior solid organ transplantation or haematopoietic stem cell transplantation
- History of hypersensitivity to the IMP or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the IMP
- Participation in other clinical trials or their observation period during the last 30 days before the first administration of the IMP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IDH1 peptide vaccine
The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®.
It is injected subcutaneously and administered in combination with topical imiquimod.
The vaccine is administered 8 times every 2 or 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety and tolerability of repeated fixed dose vaccinations of the IDH1 peptide vaccine administered with topical imiquimod (Aldara®) assessed by Regime Limiting Toxicity (RLT).
Time Frame: 15 months
|
Primary safety endpoint is the Regime Limiting Toxicity (RLT).
|
15 months
|
immunogenicity of the IDH1 peptide vaccine
Time Frame: 15 months
|
The primary immunogenicity endpoint is the presence of an IDH1R132H-specific T-cell and/or antibody response at any time point during the trial measured by IFN-gamma ELISpot and ELISA, respectively (response Yes/No).
|
15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
immunogenicity by assessing the IDH1R132H-specific T-cell and antibody response
Time Frame: 15 months
|
15 months
|
|
progression-free survival (PFS)
Time Frame: 15 months
|
15 months
|
|
overall response rate (ORR)
Time Frame: 15 months
|
15 months
|
|
association between immunogenicity (IDH1R132H-specific T-cell and antibody response) and the clinical outcome parameters (ORR, PFS)
Time Frame: 15 months
|
assessed by Logistic regression and Proportional Hazard models
|
15 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Platten, MD, University Hospital Heidelberg, Neurology Clinic; Neurooncology Program at the NCT
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT-2013-0216
- 2014-000503-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on IDH1 peptide vaccine
-
National Liver Institute, EgyptUnknownVaccine Overdose of Undetermined IntentEgypt
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Not yet recruitingNSCLC Stage IV | ALK Fusion Protein Expression
-
COL George Peoples, MD, FACSCompletedOvarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian CancerUnited States
-
University Hospital TuebingenCooperative Weichteilsarkom Study Group; Deutsches Konsortium fürTranslationale... and other collaboratorsRecruitingEwing Sarcoma | Rhabdomyosarcoma | Synovial SarcomaGermany
-
Sellas Life Sciences GroupCompletedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
Mingge LLCFudan University; Huashan HospitalActive, not recruitingGlioma, Malignant | Computer-AssistedChina
-
zeinab ahmed yousif hasan ashourRecruiting
-
Herbert LyerlyRecruiting